Normal version of the site:
Font size:
a
a
a

Innovative developments

“Alotech, 99mTc” - a new domestic radioactive pharmaceutical for imaging of sentinel lymph nodes
In recent years radionuclide research methods have proven themselves to detect the so-called sentinel lymph nodes (SLN) - the first nodes into which a malignant tumor drains. These nodes filtering afferent lymph become a trap for malignant cells, so the biopsy of SLN (with the following histological examination) is the objective diagnostic criteria of the spread of malignant process. It is supposed that if the SLN are not affected by a metastatic process, all the other regional nodes remain intact. The world's nuclear medicine has several radiopharmaceuticals (RPs) for detecting SLN. 
Preclinical studies of the drug on the basis of an oxime derivative as a neuroprotector in cerebrovascular diseases

The aim of the project was to conduct preclinical study and development of the innovative drug based on the sodium salt of 11H-indeno [1,2-b] quinoxalin-11-on-oxime (IQ-IS) as a neuroprotective agent in cerebrovascular diseases. The developed innovative drug IQ-1S is a neuroprotector with multi-targeting activity, it affects important mechanisms of neuronal damage during ischemia / reperfusion. The action of IQ-1S includes inhibition of c-Jun N-terminal kinase in brain tissue, antioxidant, hemorheological and NO-donating activity.  IQ-1S is superior in neuroprotective activity toward the neuroprotector citicoline. All the necessary preclinical studies were completed, the technology for the production of the substance and dosage form was developed, the documents for registration and clinical research were prepared. The use of IQ-1S will increase the effectiveness of cerebrovascular accidents therapy.

Preclinical studies of the innovative drug on the basis of hexaazaizowurtzitane derivative for the treatment of pain syndrome caused by different etiology

The aim of the project was to conduct preclinical studies of the drug on the basis of hexaazaizowurtzitane derivative for the treatment of pain syndrome caused by different etiology. The evaluated analgesic appeared to be unique in the scope of the patent and scientific-medical literature on the complex of technological experimental-industrial decisions, effectiveness and safety. All the necessary preclinical studies were completed, the technology for the production of the substance and dosage form was developed, the documents for registration and clinical research were prepared. The development of the economically affordable domestic drug of Thiowurtzine capcule dosage form – innovative effective and low-toxic analgesic gave the opportunity to increase the effectiveness and safety of the treatment of different nosologies, injuries and surgeries accompanied by pain syndrome, to create on the territory of the Russian Federation high-technology pharmaceutical production with high export potential.

Development of new-generation coronary stent
The project aims at the development and elaboration of the technology and infrastructure of producing Russian new-generation metallic stent with biodegradable polymer coating containing chemically modified carbon nanomaterial selectively interacting with strictly defined fractions of the lipid spectrum of bioorganic media including atherosclerotic formations on the vascular walls, destroying them, and making them accessible for further metabolizing.
Development of approach to remote personal ECG monitoring/ECG express
The project aims at the development of an approach to remote personal ECG monitoring (abnormal ST segment and cardiac arrhythmias) in patients with coronary artery disease (CAD) with high risk of the development of acute myocardial infarction and sudden cardiac death.